BCL9 Antibody

中文名稱：

BCL9兔多克隆抗體
貨號：

CSB-PA002631LA01HU
規格：

￥440
圖片：
Western Blot
Positive WB detected in: Jurkat whole cell lysate
All lanes: BCL9 antibody at 3.4µg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 150 kDa
Observed band size: 150 kDa

IHC image of CSB-PA002631LA01HU diluted at 1:200 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-PA002631LA01HU diluted at 1:200 and staining in paraffin-embedded human prostate tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of Hela cells with CSB-PA002631LA01HU at 1:67, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) BCL9 Polyclonal antibody
Uniprot No.：

O00512
基因名：

BCL9
別名：

BCL9B-cell CLL/lymphoma 9 protein antibody; B-cell lymphoma 9 protein antibody; Bcl-9 antibody; Protein legless homolog antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human B-cell CLL/lymphoma 9 protein (231-340AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，BCL9 Antibody (CSB-PA002631LA01HU)，的標記方式是Non-conjugated。對于BCL9 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA002631LB01HU	BCL9 Antibody, HRP conjugated	ELISA
FITC	CSB-PA002631LC01HU	BCL9 Antibody, FITC conjugated
Biotin	CSB-PA002631LD01HU	BCL9 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:200-1:500
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Involved in signal transduction through the Wnt pathway. Promotes beta-catenin's transcriptional activity.
基因功能參考文獻：
1. Specific regulation of BCL9 expression by HIF-1alpha may prove to be an underlying crosstalk between Wnt/beta-catenin signaling and hypoxia signaling pathways. PMID: 28074862
2. Results find that BCL9 is upregulated in osteosarcoma (OS) tissues and promotes OS proliferation, migration and invasion. BCL9 is a downstream target of miR-1301 in OS cells. In addition, BCL9 restoration could reversed the functional effects of miR-1301 overexpression on OS cell proliferation, migration and invasion. These results revealed the important role of BCL9 in OS tumor progression. PMID: 30172867
3. High BCL9 expression is associated with cisplatin-resistance in non-small cell lung cancer. PMID: 30009824
4. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/beta-catenin signaling through targeting BCL9. PMID: 28817119
5. results from this study demonstrated that hypoxia induced BCL-9 expression in human CRC cells mainly through HIF-1alpha, which could be an important underlying mechanism for increased BCL-9 expression in CRC. PMID: 27121066
6. SOX7 inhibits oncogenic beta-catenin-mediated transcription by disrupting the beta-catenin/BCL9 interaction. PMID: 29271667
7. The authors used CRISPR/Cas9 genome engineering of Drosophila legless (lgs) and human BCL9 and B9L to show that the C-terminus downstream of their adaptor elements is crucial for Wnt responses. PMID: 28296634
8. MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9. PMID: 27507882
9. it was demonstrated that miR218 modulated a novel molecular target and the present study provided novel insights into potential mechanisms of RCC oncogenesis. PMID: 27314976
10. findings indicate that BCL9 most likely does not harbor a common genetic variant that can increase the risk for schizophrenia in the Japanese population PMID: 26494551
11. BCL9/9L-beta-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer PMID: 26844272
12. BCL9 is a molecular driver of DCIS invasive progression. PMID: 26384318
13. PCDH10 antagonized MM cell proliferation via the downregulation of Wnt/beta-catenin/BCL-9 signaling, whereas PCDH10 repressed the expression of AKT to promote the expression of GSK3beta and then to restrain the activation of beta-catenin PMID: 26081897
14. By beta-catenin's association with LEF1 and BCL9-2/B9L. PMID: 24419084
15. MiR-30-5p downregulation occurs as a result of interaction between multiple myeloma cells and bone marrow stromal cells, which in turn enhances expression of BCL9. PMID: 24599134
16. we detected five SNPs in the first two genes/loci - BCL9 and C9orf5 - strongly associated with negative symptoms of schizophrenia PMID: 23382809
17. Inhibition of the BCL9-beta-catenin interaction and selectively suppresses oncogenic Wnt transcription. PMID: 22914623
18. growth factor induced proliferation mediates a neutralizing response by significantly increasing miR-30c-2* which reduces BCL9 expression and cell proliferation in SKOV-3 and OVCAR-3 cells PMID: 22024689
19. These findings indicate that common variations in the BCL9 gene confer risk of schizophrenia and may also be associated with bipolar disorder and major depressive disorder in the Chinese Han population. PMID: 21383261
20. Pygo2 PHD is the only known PHD finger that is capable of interacting simultaneously with two functional ligands, B9L and BCL9 PMID: 20637214
21. crystallographic analysis of how beta-catenin, BCL9, BCL9-2 and Tcf4 interact PMID: 17052462
22. BCL9 itself contains a transcriptional activation domain in the C terminus, which functionally synergizes in lymphoid cells with the C-terminal transactivation domain of beta-catenin. PMID: 18347063
23. Data show that human and Drosophila Pygo PHD fingers associate with their cognate HD1 domains from BCL9/Legless to bind specifically to the histone H3 tail methylated at lysine 4 (H3K4me). PMID: 18498752
24. Overexpression and altered subcellular localization of ATG16L1 protein in human oral squamous-cell carcinoma: correlation with lymphovascular invasion and lymph-node metastasis are reported. PMID: 18789482
25. The amino-terminus of the BCL9 peptide is critical for maintaining the wild-type binding affinity of the BCL9 peptide to beta-catenin. PMID: 19715304
26. Findings suggest that deregulation of BCL9 is an important contributing factor to tumor progression in multiple myeloma and colon neoplasms. PMID: 19738061
顯示更多

收起更多
相關疾病：

A chromosomal aberration involving BCL9 is found in a patient with precursor B-cell acute lymphoblastic leukemia (ALL). Translocation t(1;14)(q21;q32). This translocation leaves the coding region intact, but may have pathogenic effects due to alterations in the expression level of BCL9. Several cases of translocations within the 3'-UTR of BCL9 have been found in B-cell malignancies.
亞細胞定位：

Nucleus.
蛋白家族：

BCL9 family
組織特異性：

Detected at low levels in thymus, prostate, testis, ovary and small intestine, and at lower levels in spleen, colon and blood.
數據庫鏈接：

HGNC: 1008

OMIM: 602597

KEGG: hsa:607

STRING: 9606.ENSP00000234739

UniGene: Hs.415209

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human